People: Advanced Life Sciences Holdings Inc (ADLS.PK)


ADLS.PK on OTC Markets Group

0.04USD
19 Jun 2013
Price Change (% chg)

$0.00 (+0.24%)
Prev Close
$0.04
Open
$0.05
Day's High
$0.05
Day's Low
$0.04
Volume
21,256
Avg. Vol
4,922
52-wk High
$0.10
52-wk Low
$0.01

Search Stocks

Summary

Name Age Since Current Position

Michael Flavin

 55 1999 Chairman of the Board, Chief Executive Officer

John Flavin

 42 2010 President, Chief Financial Officer, Director

Ze-Qi Xu

 49 2002 Executive Vice President, Chief Scientific Officer

Suseelan Pookote

 57 2001 Executive Vice President - Corporate Development

Patrick Flavin

 36 2004 Chief Legal Counsel

Scott Meadow

 57 2005 Independent Director

Terry Osborn

 67 2001 Independent Director

Richard Reck

 62 2005 Independent Director

Israel Rubinstein

 59 2001 Independent Director

Rosalie Sagraves

 65 2001 Independent Director

Thomas Thornton

 45 2001 Independent Director
» Insider Trading

Biographies

Name Description

Michael Flavin

 Dr. Michael T. Flavin, Ph.D., is Chairman of the Board, Chief Executive Officer of Advanced Life Sciences Holdings, Inc. He founded Advanced Life Sciences, Inc. in 1999 and is Chairman and Chief Executive Officer. Prior to founding the Company, Dr. Flavin was the Chairman and Chief Executive Officer of MediChem Life Sciences, Inc., a drug discovery technology and services company that he also founded. Dr. Flavin took MediChem from start-up in 1987 through many stages of development, including the completion of MediChem's private placement, the acquisition and integration of ThermoGen and Emerald Biostructures as MediChem subsidiaries and MediChem's initial public offering in October 2000. MediChem was acquired in March 2002 by deCODE genetics, Inc. Dr. Flavin was the Chief Executive Officer of MediChem, as a subsidiary of deCODE genetics, Inc., through May 2002. Dr. Flavin received a B.S. in Chemistry from the University of Notre Dame, a Ph.D. in Medicinal Chemistry from the University of Illinois at Chicago and he completed a postdoctoral fellowship at Harvard University.

John Flavin

 Mr. John L. Flavin is President, Chief Financial Officer, Director of Advanced Life Sciences Holdings, Inc. He joined the Company in June 2002 as Executive Vice President and Chief Financial Officer. He was elected to the Board of Directors in 2003 and promoted to President in 2004. He led the Company's initial public offering in 2005 and subsequent follow-on equity offerings. He oversees all business, financial and operational activities of the Company. Prior to joining Advanced Life Sciences in 2002, he was instrumental in building MediChem Life Sciences, Inc. from six (6) people in 1991 to over 230 by 2002. He helped lead MediChem's private equity financing in 1999, initial public offering in 2000 and its acquisition by DeCODE genetics, Inc. in 2002. Mr. Flavin was the Chief Operating Officer and a director of MediChem and was responsible for the acquisition and management of Emerald Biostructures, ThermoGen and AXAS, which became subsidiaries of MediChem. Mr. Flavin was named the Marquette University College of Business Young Alumnus of the year in 2005 and is a KPMG Illinois High Tech Award winner. Mr. Flavin serves on the Lewis University President's Council of Regents and is a Marquette Circles Host Committee Member. He guest lectures regularly at the University of Chicago Booth Graduate School of Business in the area of biotechnology entrepreneurship. Mr. Flavin holds a B.S. in Business Administration from Marquette University and an M.B.A. from Lewis University.

Ze-Qi Xu

 Dr. Ze-Qi Xu, Ph.D., is Executive Vice President, Chief Scientific Officer of Advanced Life Sciences Holdings, Inc., since October 2002. Prior to joining, from January 2000 until September 2002, Dr. Xu was the Vice President of Strategic Drug Development of MediChem Life Sciences, Inc., where he oversaw the discovery and preclinical development of ALS-886 and ALS-357. Dr. Xu has published 54 articles and holds 21 patents in the fields of infectious disease and cancer. Dr. Xu earned a B.S. degree in Chemistry from Jiangxi Normal University (China), a M.S. degree in Organic Chemistry from Shanghai Medical University and a Ph.D. in Organic Chemistry from the Shanghai Institute of Organic Chemistry. He performed his postdoctoral fellowships at Clemson University and the Michigan Cancer Foundation.

Suseelan Pookote

 Dr. Suseelan R. Pookote, Ph.D., is Executive Vice President - Corporate Development of Advanced Life Sciences Holdings, Inc., since March 2001. Prior to joining, Dr. Pookote worked at Monsanto Company from 1980 to 2000, where he had responsibility for technology and business development in a variety of industry segments such as food, nutrition, biotechnology and specialty chemicals. At Monsanto, Dr. Pookote concentrated on technology evaluation, licensing and corporate transactions, including the negotiation of technology licensing deals with academic institutions. Dr. Pookote received his Ph.D. in Chemical Engineering from Northwestern University.

Patrick Flavin

 Mr. Patrick W. Flavin, J.D., is Chief Legal Counsel of Advanced Life Sciences Holdings, Inc. He joined in November 2002 as legal counsel. He was promoted to Chief Legal Counsel in 2004. Prior to joining, Mr. Flavin served as a counsel to the Illinois Speaker of the House from January 2002 to November 2002. Prior to this position, he was the Director of Legal Affairs for MediChem Life Sciences, Inc. from May 2000 to September 2001, where he managed the in-house legal staff and outside legal counsel. Mr. Flavin obtained his B.A. from Providence College and received his J.D. from DePaul University College of Law.

Scott Meadow

 Mr. Scott F. Meadow is an Independent Director of Advanced Life Sciences Holdings, Inc., since August 2005. Mr. Meadow is the Faculty Director of Global Initiatives and clinical professor of entrepreneurship at the University of Chicago Graduate School of Business, a position he has held since 2000. Mr. Meadow has been an Associate Partner at Edgewater Growth Capital Partners and remains a Senior Advisor. He is a principal investor in the private equity industry and has spent 25 years as a general partner, most recently at Sprout Group. Before joining Sprout Group, Mr. Meadow was a general partner focused on healthcare investing. Representative investments include the Coventry Corporation, HEALTHSOUTH Corporation, Sunrise Senior Living, Inc., Sunrise International, Managed Health Network, Inc., Aspen Education Services, Pathology Partners Inc., Heritage Healthcare, Inc. and MedPartners. In addition to his experience in the healthcare field, Mr. Meadow has been active in the consumer services sector, organizing The Sports Authority, Inc., CompUSA and Staples, Inc. Mr. Meadow holds a B.A. from Harvard College and an M.B.A. from the Harvard Business School.

Terry Osborn

 Dr. Terry W. Osborn, Ph.D., M.B.A., is an Independent Director of Advanced Life Sciences Holdings, Inc., since July 2001. Dr. Osborn is a pharmaceutical executive with experience in establishing strategic direction to develop sales and enhance profitability in startup, growth and turnaround environments. Since July 2010, he has been a member of Heartland Bio Ventures of the Kansas Bioscience Authority. In 2008, Dr. Osborn became the founding CEO of AbaStar MDc™ Inc., a molecular diagnostic company that he helped to co-found, which is developing proprietary blood-based gene expression and molecular diagnostic tests for the accurate diagnosis of mental disorders and neurodegenerative diseases. From July 2006 to 2008 Dr. Osborn assisted with the initial public offering of WaferGen Bio-Systems, Inc., which develops, manufactures, and sells systems for genome analysis for the life science and pharmaceutical industries. From 2002 until 2006, he was the President and Chief Executive Officer of Gene Express, Inc., a genomics company in Chicago, Illinois. From 1999 until July 2002, Dr. Osborn was the CEO of Pharmaceutical Development Center, a contract formulation, development and cGMP manufacturer of biopharmaceutical and pharmaceutical drugs. He was also the co-founder, President and Chief Executive Officer of Health Advance Institute, a National Clinical Research Organization providing clinical research services to pharmaceutical and biotechnology companies. His initial research and development, clinical research, manufacturing, distribution and business experience was gained at American Hospital Supply Corporation, Eli Lilly & Company, and Nichols Institute. Dr. Osborn received his Ph.D. in Biochemistry from the University of California at Riverside and his M.B.A. from Pepperdine University.

Richard Reck

 Mr. Richard A. Reck is an Independent Director of Advanced Life Sciences Holdings, Inc., since August 2005. Mr. Reck is the founder and President of Business Strategy Advisors, a consulting firm, a position he has held since August 1, 2002 and he is a Certified Public Accountant. Mr. Reck had been a partner with KPMG LLC for 30 years, having served as the National Partner-in-Charge of the Software Strategic Consulting Practice as well as the National Partner-in-Charge of the Software and Services Practice. He is currently a member of the board of directors of Merge Healthcare, a public healthcare software and services company, and Interactive Intelligence, a public communications software company. Mr. Reck holds a B.A. in mathematics from DePauw University and an M.B.A. in accounting from the University of Michigan.

Israel Rubinstein

 Dr. Israel Rubinstein, M.D., is an Independent Director of Advanced Life Sciences Holdings, Inc., since May 2001. Dr. Rubinstein is Professor of Medicine, Department of Medicine, and Affiliate Faculty, Department of Physiology and Biophysics at the University of Illinois at Chicago, where he has worked since 1993. Dr. Rubinstein is a physician and research scientist in respiratory medicine and oncology. He has served on the editorial boards of several medical and scientific journals and is grant reviewer for the National Institutes of Health. Dr. Rubinstein received an M.D. degree from Hebrew University—Hadassah School of Medicine and completed fellowships in Respirology at the University of Toronto and at the Cardiovascular Research Institute of the University of California at San Francisco. Dr. Rubinstein provides practical insight as a physician and research scientist in respiratory medicine and oncology and member of several editorial boards of medical and scientific journals.

Rosalie Sagraves

 Dr. Rosalie Sagraves, Pharm.D., is an Independent Director of Advanced Life Sciences Holdings, Inc. since May 2001. Dr. Sagraves is dean emerita and professor emerita at the University of Illinois at Chicago College of Pharmacy. She served as dean of the College from 1995 to 2006. She is currently interim chief science officer and consultant on global pharmacy education and healthcare for the American Association of Colleges of Pharmacy (AACP). Her areas of educational/research interest include pediatric pharmacotherapeutics, maternal- child health, and women's health. She has authored 90 journal articles and book chapters. She is a speaker on pediatric pharmacotherapy and women's health. She helped establish the AACP Global Pharmacy Education Special Interest Group, has served as Council of Deans chair for AACP and as a member of its board of directors, and as a member of the American Pharmacists Association (APhA) board of trustees. She has served as president of the APhA Academy of Pharmaceutical Research and Science and as associate editor and member of the editorial board of Pharmacy Today. She served as a column editor for the Journal of Pediatric Health Care. She is a fellow of APhA and of the American College of Clinical Pharmacy. She has had ongoing involvement with the Sister to Sister Foundation and its national campaigns to advance women's heart health. She served as a member of the National Institutes of Health Office of Research on Women's Health advisory committee and its Task Force, Research on Women's Health for the 21st Century. She has received awards for teaching and leadership. She attended Miami University (Ohio) and later received her B.S. in Pharmacy from The Ohio State University and a Doctor of Pharmacy (Pharm.D.) degree from the Philadelphia College of Pharmacy (University of the Sciences in Philadelphia).

Thomas Thornton

 Mr. Thomas V. Thornton, is an Independent Director of Advanced Life Sciences Holdings, Inc., since June 2001. Mr. Thornton is a early-stage venture capital investor and recognized leader in the development of public/private technology development initiatives. Since October 1, 2006, Mr. Thornton has served as the President and Chief Executive Officer of the Kansas Bioscience Authority, one of the nation's bioscience development funds. From January 2005 to October 2006, Mr. Thornton was the President of the Illinois Technology Development Alliance, a public/private partnership established to strengthen Illinois' economy through science and technology. From July 2001 to March 2002, Mr. Thornton was the Senior Vice President—Midwest Region for Convergent Technology Group, a mergers and acquisitions advisory services firm. From October 1999 to May 2001, Mr. Thornton was the Managing Partner for divine interVentures, Inc., a service and software company, and led seed-stage and early-stage venture investing teams that managed over $120 million and contributed to divine interVenture's initial public offering. Mr. Thornton received a B.A. degree from the University of Wisconsin-Madison. Mr. Thornton provides knowledge and advice on capital markets, financing and government revenue streams, and development strategies of technology-based companies.

Basic Compensation

Name Fiscal Year Total

Michael Flavin

 422,961

John Flavin

 347,145

Ze-Qi Xu

 318,258

Suseelan Pookote

 278,181

Patrick Flavin

 --

Scott Meadow

 --

Terry Osborn

 --

Richard Reck

 --

Israel Rubinstein

 --

Rosalie Sagraves

 --

Thomas Thornton

 --
As Of 30 Dec 2010

Options Compensation

Name Options Value

Michael Flavin

 0 0

John Flavin

 98,863 403,762

Ze-Qi Xu

 79,255 189,944

Suseelan Pookote

 48,870 187,370

Patrick Flavin

 0 0

Scott Meadow

 0 0

Terry Osborn

 0 0

Richard Reck

 0 0

Israel Rubinstein

 0 0

Rosalie Sagraves

 0 0

Thomas Thornton

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks